NCT04292184View on ClinicalTrials.gov

Evaluation of Thiosulfate in End Stage Renal Disease and Kidney Transplantation

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

March 21, 2021

Primary Completion Date

November 1, 2022

Study Completion Date

November 1, 2022

Conditions
End Stage Renal Disease (ESRD)
Interventions
DRUG

Seacalphyx (sodium thiosulfate pentahydrate injection BP) 25%

The kidney will have 100 mL of 500µM STS added directly to the existing pulsatile perfusion solution at 4°C.

Trial Locations (1)

N6A 5A5

London Health Sciences Centre, University Hospital, London

All Listed Sponsors
lead

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER

NCT04292184 - Evaluation of Thiosulfate in End Stage Renal Disease and Kidney Transplantation | Biotech Hunter | Biotech Hunter